CLN-049
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 60 patients (estimated)
- Sponsors
- Cullinan Therapeutics Inc.
- Tags
- Adoptive Cellular Therapy, Tyrosine Kinase (TK) Inhibitor, CD3, FLT3
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1616
- NCT Identifier
- NCT05143996
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.